ABC | Volume 111, Nº1, July 2018

Original Article Warpechowski Neto et al Brugada syndrome – cohort and 19-year registry Arq Bras Cardiol. 2018; 111(1):13-18 Figure 1 – Event-free survival curve of the patients with implantable cardioverter defibrillator (ICD). 100 90 80 70 60 50 40 30 20 10 0 Likelihood of appropriate-shock-free survival ICD (%) Patients with ICD 0 500 1000 1500 2000 2500 3000 3500 Days 18 10 6 4 4 3 3 0 Number at risk Table 2 – Characteristics regarding arrhythmia induction during the electrophysiological study With induced arrhythmia Without induced arrhythmia p Number (%) 16 (45.7) 19 (54,3) Age 44.625 (±13.69) 43,26 (± 13,30) 0.768 ¶ Male sex 12 (75) 13 (68,42) 0.7304 ¶ Electrocardiographic pattern Type I 10 11 0.8034 † Type II 6 7 Type III - 1 Clinical manifestation Asymptomatic 10 13 0.99 † Palpitations 2* 4** 0.82 † Syncope 3 2** 0.83 † FH of sudden death 2* 1 0.87 † * In the group of patients with induced arrhythmia, one had palpitations and sudden death in the family. ** In the group of patients without induced arrhythmia, one had palpitations and syncope. FH: family history. ¶ : Student t test; † : Chi-square / Fisher exact test. The worldwide prevalence of BrS is heterogeneous, because of its nonpermanent electrocardiographic tracings, disparate genetic changes or undiagnosed patients. In addition, potential arrhythmic events and sudden death can occur, making long-term follow-up important to understand the disease and elaborate tools for risk stratification and therapy, mainly because of the involvement of young individuals and the long exposure to possible outcomes. 15